tiprankstipranks
Trending News
More News >

Jasper Therapeutics Reports Positive Phase 1b/2a Study Results

Story Highlights
  • Jasper Therapeutics reported positive results from its SPOTLIGHT study on June 14, 2025.
  • Briquilimab showed high efficacy and safety in treating chronic inducible urticaria.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Jasper Therapeutics Reports Positive Phase 1b/2a Study Results

Don’t Miss TipRanks’ Half-Year Sale

Jasper Therapeutics ( (JSPR) ) just unveiled an announcement.

On June 14, 2025, Jasper Therapeutics reported positive results from the 180mg cohort of its SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic inducible urticaria. The study showed that 92% of participants achieved a complete response, and 100% achieved a clinical response, with no serious adverse events reported. The results demonstrate briquilimab’s potential to rapidly deliver robust and durable control of urticaria symptoms, supporting its development as a treatment for mast cell-driven diseases.

The most recent analyst rating on (JSPR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Spark’s Take on JSPR Stock

According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.

Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.

To see Spark’s full report on JSPR stock, click here.

More about Jasper Therapeutics

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.

Average Trading Volume: 195,117

Technical Sentiment Signal: Sell

Current Market Cap: $83.82M

Find detailed analytics on JSPR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1